<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737841</url>
  </required_header>
  <id_info>
    <org_study_id>Probio-Bifid-IBS</org_study_id>
    <nct_id>NCT00737841</nct_id>
  </id_info>
  <brief_title>Effect of Bifidobacterium on Irritable Bowel Syndrome</brief_title>
  <acronym>PBIBS</acronym>
  <official_title>Effect of Bifidobacterium on Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tohoku University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There has been no data on effect of Bifidobacterium breve on symptoms of patients with
      irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on
      symptoms of IBS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There has been no data on effect of Bifidobacterium breve on symptoms of patients with
      irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on
      symptoms of IBS patients. IBS patients will be enrolled via advertisement. Any IBS subtypes
      will not be rejected. They will take either 1.0 g of Bifidobacterium breve 3 times a day or
      same amount of placebo for 8 weeks. IBS symptoms and allied markers will be checked before,
      during, and after the administration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">September 2008</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate relief and SIBSQ</measure>
    <time_frame>2, 0, 2, 4, 8 weeks during treatment and 4 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychometric test, bowel gas, blood, and feces.</measure>
    <time_frame>2, 0, 2, 4, 8 weeks during treatment and 4 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium breve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium breve</intervention_name>
    <description>1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1.0 g of placebo, taking orally, 3 times a day for 8 weeks.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IBS with Rome II definition

        Exclusion Criteria:

          -  Diagnosis of serious diseases (both physically and mentally)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin Fukudo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tohoku University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shin Fukudo, MD, PhD</last_name>
    <phone>+81-22-717-8214</phone>
    <email>sfukudo@mail.tains.tohoku.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Machiko Watabe</last_name>
    <phone>+81-22-717-8162</phone>
    <email>wmachiko@mail.tains.tohoku.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tohoku University Graduate School of Medicine</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Fukudo, MD, PhD</last_name>
      <phone>+81-22-717-8214</phone>
      <email>sfukudo@mail.tains.tohoku.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Machiko Watabe</last_name>
      <phone>+81-22-717-8162</phone>
      <email>wmachiko@mail.tains.tohoku.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>August 19, 2008</last_update_submitted>
  <last_update_submitted_qc>August 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Shin Fukudo</name_title>
    <organization>Tohoku University Graduate School of Medicine</organization>
  </responsible_party>
  <keyword>stress</keyword>
  <keyword>brain-gut interactions</keyword>
  <keyword>visceral perception</keyword>
  <keyword>gastrointestinal motility</keyword>
  <keyword>emotion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 7, 2009</submitted>
    <returned>November 9, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

